Cargando…

Olmesartan Medoxomil, An Angiotensin II-Receptor Blocker, Ameliorates Renal Injury In db/db Mice

BACKGROUND: Diabetic nephropathy (DN) is a common complication of diabetes mellitus (DM) and also a major cause of end-stage renal disease (ESRD). Olmesartan medoxomil (OM) is an angiotensin II receptor blocker (ARB) and has been shown to exhibit renoprotective effects on a streptozotocin (STZ)-indu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhu, Ye, Li, Ze-Liang, Ding, Ao, Yang, Hui, Zhu, Wei-Ping, Cui, Tong-Xia, Zhang, Hui-Tao, Zhang, Hua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6815789/ https://www.ncbi.nlm.nih.gov/pubmed/31695333 http://dx.doi.org/10.2147/DDDT.S217826

Ejemplares similares

Effect of angiotensin receptor blockade on endothelial function: focus on olmesartan medoxomil
por: Ferrario, Carlos
Publicado: (2009)

Olmesartan medoxomil combined with hydrochlorothiazide for the treatment of hypertension
por: Greathouse, Mark
Publicado: (2006)

Spectrophotometric Estimation of Olmesartan Medoxomil and Hydrochlorothiazide in Tablet
por: Rote, A. R., et al.
Publicado: (2010)

Olmesartan medoxomil for the treatment of hypertension in children and adolescents
por: Tocci, Giuliano, et al.
Publicado: (2011)

Formulation and Evaluation of Liquisolid Compacts for Olmesartan Medoxomil
por: Prajapati, Shailesh T., et al.
Publicado: (2013)

Olmesartan medoxomil: Allergic reaction: case report
Publicado: (2022)

Astragaloside IV ameliorates renal injury in db/db mice
por: Sun, Huili, et al.
Publicado: (2016)

Shengmai San Ameliorates Myocardial Dysfunction and Fibrosis in Diabetic db/db Mice
por: Zhao, Juan, et al.
Publicado: (2016)

Olmesartan medoxomil: current status of its use in monotherapy
por: Brunner, Hans R
Publicado: (2006)

Development and characterization of nanosuspensions of olmesartan medoxomil for bioavailability enhancement
por: Thakkar, Hetal Paresh, et al.
Publicado: (2011)

Small bowel enteropathy associated with olmesartan medoxomil treatment
por: Galanopoulos, Michail, et al.
Publicado: (2017)

Olmesartan-medoxomil: Sprue-like enteropathy: case report
Publicado: (2021)

Evaluation of the angiotensin II receptor blocker azilsartan medoxomil in African‐American patients with hypertension
por: Johnson, Wallace, et al.
Publicado: (2017)

Adiponectin retards the progression of diabetic nephropathy in db/db mice by counteracting angiotensin II
por: Guo, Xiaohua, et al.
Publicado: (2014)

Integrated control of hypertension by olmesartan medoxomil and hydrochlorothiazide and rationale for combination
por: Punzi, Henry A
Publicado: (2011)

Linear mixed‐effects model of QTc prolongation for olmesartan medoxomil
por: Song, SaeHeum, et al.
Publicado: (2016)

Olmesartan medoxomil reverses glomerulosclerosis in renal tissue induced by myocardial infarction without changes in renal function
por: LU, XIAO-MEI, et al.
Publicado: (2014)

Simultaneous Estimation of Amlodipine Besilate and Olmesartan Medoxomil in Pharmaceutical Dosage Form
por: Wankhede, S. B., et al.
Publicado: (2009)

Human Carboxymethylenebutenolidase as a Bioactivating Hydrolase of Olmesartan Medoxomil in Liver and Intestine
por: Ishizuka, Tomoko, et al.
Publicado: (2010)

Design of Olmesartan Medoxomil-Loaded Nanosponges for Hypertension and Lung Cancer Treatments
por: Almutairy, Bjad K., et al.
Publicado: (2021)

Astragaloside IV ameliorates diabetic nephropathy in db/db mice by inhibiting NLRP3 inflammasome-mediated inflammation
por: Feng, Hui, et al.
Publicado: (2021)

Exploring the Effectiveness and Safety of Azilsartan-Medoxomil/Chlorthalidone Versus Olmesartan-Medoxomil/Hydrochlorothiazide in Hypertensive Patients: A Meta-Analysis
por: Kumar, Lakshya, et al.
Publicado: (2023)

Mycophenolate Mofetil Ameliorates Diabetic Nephropathy in db/db Mice
por: Seo, Jung-Woo, et al.
Publicado: (2015)

Melatonin ameliorates hepatic steatosis by inhibiting NLRP3 inflammasome in db/db mice
por: Yu, Yongxiang, et al.
Publicado: (2021)

Antihypertensive efficacy of the angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril
por: Bönner, G, et al.
Publicado: (2013)

The Clinical Efficacy of Clopidogrel Bisulfate Tablets Combined with Olmesartan Medoxomil for Ischemic Stroke with Hypertension and the Effect of Angiotensin II Type 1 Receptor Level on Prognosis
por: Yu, Jia, et al.
Publicado: (2021)

Dai-Zong-Fang, A Traditional Chinese Herbal Formula, Ameliorates Insulin Resistance in db/db Mice
por: Zhu, Lili, et al.
Publicado: (2018)

Optimal therapeutic strategy for treating patients with hypertension and atherosclerosis: focus on olmesartan medoxomil
por: Mason, R Preston
Publicado: (2011)

Derivative and Q-analysis Spectrophotometric Methods for Estimation of Hydrochlorothiazide and Olmesartan Medoxomil in Tablets
por: Bhusari, K. P., et al.
Publicado: (2009)

Efficacy and tolerability of amlodipine plus olmesartan medoxomil in patients with difficult-to-treat hypertension
por: Chrysant, S G, et al.
Publicado: (2010)

Development of Transdermal Oleogel Containing Olmesartan Medoxomil: Statistical Optimization and Pharmacological Evaluation
por: El-Dahmy, Rania Moataz, et al.
Publicado: (2023)

Efficacy and safety of azilsartan medoxomil, an angiotensin receptor blocker, in Korean patients with essential hypertension
por: Juhasz, Attila, et al.
Publicado: (2018)

Efficacy and Safety Study of Olmesartan Medoxomil, Amlodipine, and Hydrochlorothiazide Combination Therapy in Patients with Hypertension Not Controlled with Olmesartan Medoxomil and Hydrochlorothiazide Combination Therapy: Results of a Randomized, Double-Blind, Multicenter Trial
por: Sohn, Il Suk, et al.
Publicado: (2015)

Erratum to: Efficacy and Safety Study of Olmesartan Medoxomil, Amlodipine, and Hydrochlorothiazide Combination Therapy in Patients with Hypertension Not Controlled with Olmesartan Medoxomil and Hydrochlorothiazide Combination Therapy: Results of a Randomized, Double-Blind, Multicenter Trial
por: Sohn, Il Suk, et al.
Publicado: (2016)

Inhibition of acid sphingomyelinase activity ameliorates endothelial dysfunction in db/db mice
por: Jiang, Meng, et al.
Publicado: (2019)

Huangqi decoction ameliorates kidney injury in db/db mice by regulating the BMP/Smad signaling pathway
por: Chen, Ying, et al.
Publicado: (2023)

EGCG Attenuates Renal Damage via Reversing Klotho Hypermethylation in Diabetic db/db Mice and HK-2 Cells
por: Yang, Xiu Hong, et al.
Publicado: (2020)

Pharmacologic Activation of Angiotensin-Converting Enzyme II Alleviates Diabetic Cardiomyopathy in db/db Mice by Reducing Reactive Oxidative Stress
por: Kim, Donghyun, et al.
Publicado: (2023)

A Competent and Commercially Viable Process for the Synthesis of the Anti-Hypertensive Drug Olmesartan Medoxomil
por: Hanumantha Rao, Bommena, et al.
Publicado: (2015)

Enhanced ex vivo intestinal absorption of olmesartan medoxomil nanosuspension: Preparation by combinative technology
por: Attari, Zenab, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_38kjans9c7q1ursre6logjsl7m